Form 4: Axsome Therapeutics Director Acquires Stock Options in Lieu of Cash Compensation

Director Roger Jeffs acquired 1,425 stock options in Axsome Therapeutics in lieu of cash compensation earned in 2023.

Summary

• Roger Jeffs, a director of Axsome Therapeutics, acquired 1,425 stock options on February 27, 2024.
• The options were received in lieu of cash compensation earned in 2023.
• The exercise price of the options is $84.
• The options are immediately exercisable and expire on February 26, 2034.
• Following the transaction, Jeffs directly owns 1,425 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider activity. The director taking options in lieu of cash is a slightly positive signal.

Positives

• A director taking compensation in stock options aligns their interests with shareholders.

Industry Context

This is a routine disclosure of insider transactions. It is common for directors to receive stock options as part of their compensation.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical industry.
• Stock options are a common component of executive and director compensation, aligning their interests with shareholder value.
• The specific number of options and exercise price would need to be compared to similar companies to assess if it is within industry norms.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it aligns the director's interests with the company's stock performance.

Key Dates